The frequency and severity of the related adverse events covered by these algorithms will depend on the immuno-oncology agent or regimen being used. Revised Protocol No.: 04 Date: 31-May-2019 193 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 194 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 195 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 196 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Refer to http://livertox.nih.gov/ for a compendium of agents that may cause liver injury Revised Protocol No.: 04 Date: 31-May-2019 197 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 198 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 199 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Revised Protocol No.: 04 Date: 31-May-2019 200 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS APPENDIX 7 EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG) PERFORMANCE STATUS Revised Protocol No.: 04 Date: 31-May-2019 201 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS APPENDIX 8 CONSORT PUBLISHING REQUIREMENTS The Consolidated Standards of Reporting Trials (CONSORT) encompasses various initiatives developed by the CONSORT Group to alleviate th e problems arisi ng from inadequate reporting of randomized controlled trials. The CONSORT Statement The main product of CONSORT is the CONSORT Statemen t, which is an evidence-based, minimum set of recommendations for reporting randomized trials.